<DOC>
	<DOCNO>NCT02698475</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety ustekinumab pediatric participant age great equal ( &gt; = ) 6 less ( &lt; ) 12 year moderate severe chronic plaque psoriasis</brief_summary>
	<brief_title>An Efficacy , Safety , Pharmacokinetics Study Subcutaneously Administered Ustekinumab Treatment Moderate Severe Chronic Plaque Psoriasis Pediatric Participants Greater Than 6 Less Than 12 Years Age</brief_title>
	<detailed_description>This open label ( identity study drug know participant study staff ) multicenter ( one hospital medical school team work medical research study ) study . The participant population comprise boy girls diagnosis plaque psoriasis least 6 month prior first study drug administration moderate severe disease define Psoriasis Area Severity Index score ( PASI ) &gt; =12 , Physician 's Global Assessment ( PGA ) &gt; =3 , Body Surface Area ( BSA ) &gt; =10 percent ( % ) . The study consist Screening Phase ( 10 week administration study drug ) , Treatment Period ( Week 0 Week 52 ) Safety follow ( Week 56 ) . Participants primarily evaluate efficacy , pharmacokinetics ( PK ) safety .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Ustekinumab</mesh_term>
	<criteria>Participants diagnosis plaquetype psoriasis without psoriatic arthritis ( PsA ) least 6 month prior first administration study drug , widespread lesion define Psoriasis Area Severity Index score ( PASI ) great equal ( &gt; = ) 12 , Physician 's Global Assessment ( PGA ) &gt; =3 , involve body surface area ( BSA ) &gt; =10 percent ( % ) Participants candidate phototherapy systemic treatment psoriasis ( either naive history previous treatment ) psoriasis consider investigator poorly control topical therapy adequate dose duration therapy Participants consider eligible accord protocol define tuberculosis ( TB ) screen criteria Participants must positive protective antibody titer varicella measles prior first administration study drug . In absence positive protective antibody titer , participant must documentation ageappropriate vaccination varicella and/or measles ( include dos vaccine ) verification past varicella and/or measles infection document health care provider Participants must agree receive live virus live bacterial vaccination least 2 week ( longer indicate package insert relevant vaccine ) prior first administration study drug , study , within 15 week last administration study drug Participants must agree receive Bacille CalmetteGuerin ( BCG ) vaccination within 12 month screen , study , within 12 month last administration study drug Participants currently nonplaque form psoriasis ( example , erythrodermic , guttate , pustular ) Have receive systemic immunosuppressant ( example methotrexate [ MTX ] , azathioprine , cyclosporine , 6thioguanine , mercaptopurine , mycophenolate mofetil , hydroxyurea , tacrolimus ) within 4 week first administration study drug Have receive biologic agent ( example ENBREL , HUMIRA ) within previous 3 month 5 time t1/2 agent , whichever longer Have history chronic recurrent infectious disease Have history latent active granulomatous infection Have know malignancy history malignancy Have know history lymphoproliferative disease , include lymphoma , sign symptom suggestive possible lymphoproliferative disease</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Psoriasis</keyword>
	<keyword>Ustekinumab</keyword>
	<keyword>STELARA</keyword>
</DOC>